Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.23), $0.04 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $31.9 million versus the consensus estimate of $33.86 million.

GUIDANCE:

Halozyme Therapeutics sees 2016 revenue of $145-150 million, versus the consensus of $146.6 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.